Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of intravitreal Aflibercept (VEGF Trap-Eye) versus laser for diabetic macular edema
2010-022364-12Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2010
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in diabetic macular edema (DME) (2 arms), sponsored by Bayer. Primary endpoint: Change in best corrected visual acuity at week 52. Started Dec 2010; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2010-022364-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022364-12.